The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study.

"Declarations Ethics approval and consent to participateThe Comitato Etico Azienda Sanitaria Locale 1 Avezzano/Sulmona/L’Aquila, L’Aquila, Italy (protocol number 0218811/19) approved the study, which was performed according to the Good Clinical Practice guidelines and the latest Declaration of Helsinki. Written informed consents for involved patients were collected. Clinical data are kept in accordance with the EU General Data Protection Regulations (GDPR), or other counterparts, on the processing of personal data and the protection of privacy (2016/679/EU). Consent for publicationNot applicable, all the patients’ data are de-identified. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding The research was supported by an unrestricted grant from Pfizer."